Anaptys Announces Stock Repurchase Plan
AnaptysBio (ANAB) has announced a $75 million Stock Repurchase Plan authorized by its Board of Directors. The clinical-stage biotechnology company maintains a strong financial position with over $420 million in cash, cash equivalents, and investments as of December 31, 2024.
The company expects to receive a $75 million commercial sales milestone payment from GSK in 2025 or 2026. Despite the potential full execution of the buyback plan, AnaptysBio reaffirms its cash runway guidance through year-end 2027 for its R&D plan, excluding future royalties from its GSK immuno-oncology collaboration.
The stock repurchase program will run through December 31, 2025, with shares to be bought in open market transactions under Rules 10b5-1 and 10b-18. The company maintains flexibility to suspend or discontinue the program at any time.
AnaptysBio (ANAB) ha annunciato un piano di riacquisto azionario da 75 milioni di dollari autorizzato dal suo Consiglio di Amministrazione. L'azienda biotecnologica in fase clinica mantiene una solida posizione finanziaria con oltre 420 milioni di dollari in contante, equivalenti di cassa e investimenti al 31 dicembre 2024.
L'azienda prevede di ricevere un pagamento per traguardo di vendite commerciali da 75 milioni di dollari da GSK nel 2025 o 2026. Nonostante la potenziale piena attuazione del piano di riacquisto, AnaptysBio conferma la sua guida sulla liquidit脿 fino alla fine del 2027 per il suo piano di R&D, escludendo le future royalty dalla collaborazione immuno-oncologica con GSK.
Il programma di riacquisto azionario si svolger脿 fino al 31 dicembre 2025, con azioni da acquistare in transazioni sul mercato aperto secondo le Regole 10b5-1 e 10b-18. L'azienda mantiene la flessibilit脿 di sospendere o interrompere il programma in qualsiasi momento.
AnaptysBio (ANAB) ha anunciado un plan de recompra de acciones de 75 millones de d贸lares autorizado por su Junta Directiva. La empresa biotecnol贸gica en etapa cl铆nica mantiene una s贸lida posici贸n financiera con m谩s de 420 millones de d贸lares en efectivo, equivalentes de caja e inversiones al 31 de diciembre de 2024.
La compa帽铆a espera recibir un pago por hito de ventas comerciales de 75 millones de d贸lares de GSK en 2025 o 2026. A pesar de la posible ejecuci贸n completa del plan de recompra, AnaptysBio reafirma su gu铆a de liquidez hasta finales de 2027 para su plan de I+D, excluyendo regal铆as futuras de su colaboraci贸n en inmuno-oncolog铆a con GSK.
El programa de recompra de acciones se llevar谩 a cabo hasta el 31 de diciembre de 2025, con acciones que se comprar谩n en transacciones en el mercado abierto bajo las Reglas 10b5-1 y 10b-18. La empresa mantiene la flexibilidad para suspender o interrumpir el programa en cualquier momento.
AnaptysBio (ANAB)電� 鞚挫偓須岇棎靹� 鞀轨澑頃� 7500毵� 雼煬 攴滊鞚� 鞛愳偓欤� 毵れ瀰 瓿勴殟鞚� 氚滍憸頄堨姷雼堧嫟. 鞚� 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 須岇偓電� 2024雲� 12鞗� 31鞚� 旮办鞙茧 4鞏� 2000毵� 雼煬 鞚挫儊鞚� 順勱笀, 順勱笀靹� 鞛愳偘 氚� 韴瀽毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
須岇偓電� 2025雲� 霕愲姅 2026雲勳棎 GSK搿滊秬韯� 7500毵� 雼煬鞚� 靸侅梾 韺愲Г 鞚挫爼響� 歆�旮夓暋鞚� 氚涭潉 瓴冹溂搿� 鞓堨儊頃橁碃 鞛堨姷雼堧嫟. 鞛愳偓欤� 毵れ瀰 瓿勴殟鞚� 鞕勳爠頃� 鞁ろ枆 臧�電レ劚鞐愲弰 攵堦惮頃橁碃, AnaptysBio電� GSK鞕�鞚� 氅挫棴 膦呾枒頃� 順戩梾鞐愳劀 氚滌儩頃橂姅 頄ロ泟 搿滌棿韹半ゼ 鞝滌櫢頃橁碃 2027雲� 鞐半旯岇 R&D 瓿勴殟鞚� 鞙勴暅 順勱笀 鞖挫榿 歆�旃潉 鞛檿鞚疙暕雼堧嫟.
鞛愳偓欤� 毵れ瀰 頂勲攴鸽灗鞚� 2025雲� 12鞗� 31鞚�旯岇 歆勴枆霅橂┌, 10b5-1 氚� 10b-18 攴滌爼鞐� 霐半澕 瓿店皽 鞁滌灔 瓯半灅鞐愳劀 欤检嫕鞚� 毵れ瀰頃╇媹雼�. 須岇偓電� 鞏胳牅霌犾 頂勲攴鸽灗鞚� 欷戨嫧頃橁卑雮� 膦呺頃� 靾� 鞛堧姅 鞙犾棸靹膘潉 鞙犾頃╇媹雼�.
AnaptysBio (ANAB) a annonc茅 un plan de rachat d'actions de 75 millions de dollars autoris茅 par son Conseil d'administration. La soci茅t茅 biopharmaceutique en phase clinique maintient une solide position financi猫re avec plus de 420 millions de dollars en liquidit茅s, 茅quivalents de liquidit茅s et investissements au 31 d茅cembre 2024.
La soci茅t茅 s'attend 脿 recevoir un paiement d'茅tape de vente commerciale de 75 millions de dollars de GSK en 2025 ou 2026. Malgr茅 la possibilit茅 d'une ex茅cution compl猫te du plan de rachat, AnaptysBio r茅affirme ses pr茅visions de liquidit茅s jusqu'脿 la fin de 2027 pour son plan de R&D, excluant les redevances futures de sa collaboration en immuno-oncologie avec GSK.
Le programme de rachat d'actions se d茅roulera jusqu'au 31 d茅cembre 2025, avec des actions 脿 acheter dans le cadre de transactions sur le march茅 ouvert conform茅ment aux r猫gles 10b5-1 et 10b-18. L'entreprise conserve la flexibilit茅 de suspendre ou d'arr锚ter le programme 脿 tout moment.
AnaptysBio (ANAB) hat einen Aktienr眉ckkaufplan 眉ber 75 Millionen Dollar angek眉ndigt, der von seinem Vorstand genehmigt wurde. Das biopharmazeutische Unternehmen in der klinischen Phase verf眉gt 眉ber eine starke finanzielle Basis mit 眉ber 420 Millionen Dollar an Bargeld, Zahlungsmittel盲quivalenten und Investitionen zum 31. Dezember 2024.
Das Unternehmen erwartet, im Jahr 2025 oder 2026 eine Meilensteinzahlung f眉r kommerzielle Verk盲ufe in H枚he von 75 Millionen Dollar von GSK zu erhalten. Trotz der m枚glichen vollst盲ndigen Umsetzung des R眉ckkaufplans bekr盲ftigt AnaptysBio seine Liquidit盲tsprognose bis Ende 2027 f眉r seinen F&E-Plan, ohne zuk眉nftige Lizenzgeb眉hren aus der Zusammenarbeit mit GSK im Bereich Immunonkologie.
Das Aktienr眉ckkaufprogramm l盲uft bis zum 31. Dezember 2025, wobei die Aktien im Rahmen von Transaktionen auf dem offenen Markt gem盲脽 den Regeln 10b5-1 und 10b-18 gekauft werden. Das Unternehmen beh盲lt sich die Flexibilit盲t vor, das Programm jederzeit auszusetzen oder einzustellen.
- Strong cash position of over $420 million
- Additional $75M milestone payment expected from GSK
- Stock buyback program indicates confidence in company value
- Confirmed cash runway through 2027 despite buyback
- Potential future royalties from GSK collaboration not included in guidance
- Buyback reduces cash available for R&D investments
- Program may not be fully executed if market conditions are unfavorable
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to
Anaptys has cash, cash equivalents and investments greater than
The shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-18 of the Exchange Act. The timing, number of shares repurchased, and prices paid for the stock under this program will depend on general business and market conditions as well as corporate and regulatory limitations, prevailing stock prices, and other considerations. The Stock Repurchase Plan will expire on聽December 31, 2025, may be suspended or discontinued at any time, and does not obligate the company to acquire any amount of common stock.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, a CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, entering a Phase 1 trial. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli聽(dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit聽聽or follow us on聽.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the company鈥檚 ability to execute the Stock Repurchase Plan, in whole or in part; the company鈥檚 projected cash runway, and the potential to receive any additional milestones or royalties from the GSK collaboration. Statements including words such as 鈥減lan,鈥� 鈥渃ontinue,鈥� 鈥渆xpect,鈥� or 鈥渙ngoing鈥� and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company鈥檚 actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company鈥檚 ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company鈥檚 ability to fund development activities and achieve development goals, the company鈥檚 ability to protect intellectual property and other risks and uncertainties described under the heading 鈥淩isk Factors鈥� in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
FAQ
How much is AnaptysBio's (ANAB) stock repurchase program worth?
When will ANAB's stock buyback program expire?
What is AnaptysBio's (ANAB) current cash position as of December 2024?
What milestone payment does ANAB expect from GSK?
How long does ANAB expect its cash runway to last?
